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OBJECTIVE: To evaluate work productivity and associated costs
in patients with Major Depressive Disorder (MDD) treated with
escitalopram compared to patients treated with the Serotonin-
Noradrenaline Reuptake Inhibitor (SNRI) duloxetine, from
the perspective of US employers. METHODS: A multinational
pharmacoeconomic evaluation was conducted in parallel with
a 24-week double-blind randomized study [1] [escitalopram
20 mg/day (n = 139) and duloxetine 60 mg/day (n = 144)] in
adult outpatients with MDD, with a baseline Montgomery-
Åsberg Depression Rating Scale score of 26 and a Clinical
Global Impression of Severity (CGI-S) score of a current MDD
episode of 12 weeks to 1 year. Sick leave due to depression was
evaluated prospectively in a Health Economic Assessment ques-
tionnaire. Wage rates were obtained from the US Bureau of
Labor Statistics for 2006 (mean $18.8/hour, all occupations).
RESULTS: Escitalopram was associated with shorter sick leave
duration compared to duloxetine (30.7 vs. 62.2 days/patient with
sick leave, p = 0.007; 7.3 days vs. 13.0 days/patient overall,
p = 0.10). By study end, the total number of workdays lost for
the 33 patients reporting sick leave in the escitalopram arm was
1014 vs. 1866 days for the 30 patients with sick leave in the
duloxetine arm. This resulted in total costs due to lost work
productivity of $152,830 in the escitalopram group compared
with $281,244 in the duloxetine group, yielding savings over the
study timeframe (24 weeks) of $128,413 in favor of escitalopram
(p = 0.044). CONCLUSION: Escitalopram was superior to the
SNRI duloxetine in improvement of work productivity for
patients with MDD, and resulted in associated cost savings to the
US payer. With indirect cost due to sick leave accounting for the
largest portion of the total social MDD burden, these advantages
support the use of escitalopram as a ﬁrst-line treatment of MDD
in the US. [1] Wade AG, Gembert K, Florea I. Curr Med Res
Opin 2007;23:1605–1614.
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OBJECTIVE: From a societal perspective, we determined the
cost-effectiveness of a general practitioner-based minimal inter-
vention strategy for workers with stress-related sick leave (MISS)
compared to usual care (UC) in terms of: 1. quality-adjusted life
years (QALYs) and 2. total sick leave. METHODS: We con-
ducted a pragmatic, cluster-randomized controlled trial with a
12-month follow-up. Forty-six general practitioners (GPs) were
randomized to either MISS (N = 24) or UC (N = 22). From a
total source population of 22,740 patients, 433 participated
(MISS = 227; UC = 206). Data were collected from GP data-
bases, questionnaires (e.g. EuroQol) and telephone interviews. A
cost-utility and net monetary beneﬁt (NMB) analysis were con-
ducted to address each objective, respectively. Missing values
were imputed by multiple imputation. The main analyses were
based on the imputed dataset. Uncertainty was estimated by 95%
conﬁdence intervals, cost-effectiveness planes and acceptability
curves. Sensitivity analyses were conducted, and ancillary analy-
ses based on three preplanned subgroups were performed.
RESULTS: No statistically between-group differences in resource
use, costs or outcomes were observed. The mean cost per QALY
was -€7356 whereby the MISS was slightly more effective
and less expensive than UC. The probability of MISS being
cost-effective ranged from 0.58–0.90 for willingness-to-pay (l)
thresholds from €0–€100,000 per QALY. The mean NMB of the
MISS was €937 (95% CI: -1602;3476) for a l-value of €35 for
an hour less of sick leave; the corresponding probability was
0.72. Sensitivity analysis did not alter our conclusions. For the
subgroup, stress mental disorders, the mean cost per QALY was
-€28,278 (Quadrant II); the probability of MISS being cost-
effective was 0.92 or greater for all l-values. The mean NMB was
€4584 (95% CI: 306;8861). CONCLUSION: The minimal inter-
vention was not found to be more cost-effective than usual
care. It may, however, be cost-effective for the subgroup, stress-
related mental disorders. Future research is needed to conﬁrm
this observation.
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OBJECTIVE: To compare the cost-effectiveness of once-daily
methylphenidate (OROS-MPH), atomoxetine and combined
MPH/behavioral therapy in the treatment of ADHD in children
6–18 years of age, from a societal perspective. METHODS: A
decision tree was used to model response rates, costs and utilities
for the three treatment arms over a two-year period (base-case)
using evidence from clinical and economic literature. Costs &
utilities were extrapolated for a 16-year period beyond base-case
period until the patient reached adulthood. Both costs and utili-
ties were discounted at the rate of 3%. A one-way sensitivity
analysis of the ICERs was conducted to test assumptions made
while modeling and to determine drivers of cost. RESULTS: The
base-case costs and QALYs for OROS-MPH, atomoxetine and
combined therapy were US$ 8314, 9716, 10,723 and, 1.71, 1.73,
1.50 respectively. The extrapolated 12-year costs and QALYs
were US$ 21,804, 25,435, 28,759 and, 6.28, 6.21, 6.08 respec-
tively. The base-case CE ratios for stimulant, non-stimulant and
combined therapy against no-treatment are US$ 8690.2, 12577
and 57,971.9 respectively. The base-case cost-effectiveness ratio
of atomoxetine versus OROS-MPH is $60,782, while that of
combined therapy against each of the other two interventions
was negative. Sensitivity analysis showed that maintenance rates
and utilities were the main drivers of cost-effectiveness. CON-
CLUSION: All three interventions are cost-effective as compared
to no treatment option. Combined therapy was ‘dominated’ both
during the base-case as well as over long term periods. While
atomoxetine is more cost-effective than OROS-MPH over a
two-year period, the latter is the ‘dominant’ strategy over the
long term.
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